http://www.unboundmedicine.com/medline/ebm/research/daclizumabUnbound MEDLINE is a service provided by Unbound Medicine, Inc. that includes data and services from the U.S. National Library of Medicine's MEDLINE® and PubMed® databases.en-usUnbound Medicine, Inc.http://www.unboundmedicine.com/medline/ebm/record/19920920/full_citation/The_evolving_role_of_alemtuzumab__Campath_1H__in_renal_transplantation_Pham PT, Lipshutz GS, Pham PT, et al. 
The evolving role of alemtuzumab (Campath-1H) in renal transplantation. [JOURNAL ARTICLE]
Drug Des Devel Ther 2009.:41-49.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19891046/full_citation/Low_toxicity_regimens_in_renal_transplantation:_a_country_subset_analysis_of_the_Symphony_study_Demirbas A, Hugo C, Grinyó J, et al. 
Low toxicity regimens in renal transplantation: a country subset analysis of the Symphony study. [Journal Article, Research Support, Non-U.S. Gov't]
Transpl Int 2009 Dec; 22(12):1172-81.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19877219/full_citation/A_prospective_randomized_open_study_in_liver_transplant_recipients:_Daclizumab_mycophenolate_mofetil_and_tacrolimus_versus_tacrolimus_and_steroids_Otero A, Varo E, de Urbina JO, et al. 
A prospective randomized open study in liver transplant recipients: Daclizumab, mycophenolate mofetil, and tacrolimus versus tacrolimus and steroids. [JOURNAL ARTICLE]
Liver Transpl 2009 Oct 28; 15(11):1542-1552.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19857687/full_citation/Immunosuppression_With_Low_Dose_Daclizumab_in_Liver_Transplant_Recipients_With_Impaired_Kidney_Function:_A_Single_Center_Experience_Post M, Raszeja-Wyszomirska J, Jarosz K, et al. 
Immunosuppression With Low-Dose Daclizumab in Liver Transplant Recipients With Impaired Kidney Function: A Single-Center Experience. [JOURNAL ARTICLE]
Transplant Proc 2009 Oct; 41(8):3107-3109.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19857686/full_citation/Safety_and_Efficacy_of_Steroid_Free_Immunosuppression_with_Tacrolimus_and_Daclizumab_in_Liver_Transplant_Recipients:_6_Year_Follow_up_in_a_Single_Center_Foroncewicz B, Mucha K, Ryszkowska E, et al. 
Safety and Efficacy of Steroid-Free Immunosuppression with Tacrolimus and Daclizumab in Liver Transplant Recipients: 6-Year Follow-up in a Single Center. [JOURNAL ARTICLE]
Transplant Proc 2009 Oct; 41(8):3103-3106.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19855425/full_citation/Transplantation:_Personalizing_induction_therapy_in_kidney_transplantation_Aull MJ, Suthanthiran M 
Transplantation: Personalizing induction therapy in kidney transplantation. [Journal Article]
Nat Rev Nephrol 2009 Nov; 5(11):619-20.
Full Citation | Publisher Full Text | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19844746/full_citation/Effects_of_steroid_avoidance_and_novel_protocols_on_growth_in_paediatric_renal_transplant_patients_Grenda R 
Effects of steroid avoidance and novel protocols on growth in paediatric renal transplant patients. [JOURNAL ARTICLE]
Pediatr Nephrol 2009 Oct 21.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19808924/full_citation/Effects_of_Exenatide_Alone_and_in_Combination_with_Daclizumab_on_Beta_Cell_Function_in_Long_Standing_Type_1_Diabetes_Mellitus_Rother KI, Spain LM, Wesley RA, et al. 
Effects of Exenatide Alone and in Combination with Daclizumab on Beta Cell Function in Long-Standing Type 1 Diabetes Mellitus. [JOURNAL ARTICLE]
Diabetes Care 2009 Oct 6.
Abstract | Full Citationhttp://www.unboundmedicine.com/medline/ebm/record/19796497/full_citation/2007_Update_on_Allogeneic_Islet_Transplantation_from_the_Collaborative_Islet_Transplant_Registry__CITR__Group TC 
2007 Update on Allogeneic Islet Transplantation from the Collaborative Islet Transplant Registry (CITR). [JOURNAL ARTICLE]
Cell Transplant 2009 Sep 28.
Abstract | Full Citation | Find Related Articles http://www.unboundmedicine.com/medline/ebm/record/19788505/full_citation/Disengaging_the_IL_2_Receptor_with_Daclizumab_Enhances_IL_7_Mediated_Proliferation_of_CD4_+__and_CD8_+__T_Cells_Monti P, Brigatti C, Heninger AK, et al. 
Disengaging the IL-2 Receptor with Daclizumab Enhances IL-7-Mediated Proliferation of CD4(+) and CD8(+) T Cells. [JOURNAL ARTICLE]
Am J Transplant 2009 Sep 25.
Abstract | Full Citation | Publisher Full Text | Find Related Articles